started · updated
Elanco reports US$ 1.3 billion in third quarter revenue
Elanco Animal Health reported third-quarter revenue of US$ 1.3 billion for 2026, representing an 11% increase compared to the same period the previous year. On an organic basis, excluding the impact of the AHV International acquisition and constant currency effects, growth reached 9%.
The company reversed a previous loss to record a net profit of US$ 18.0 million, compared to a net loss of US$ 34.0 million in the third quarter of 2025. Following these results, Elanco has raised its financial guidance for the end of the 2026 fiscal year.
The Pet Health division led commercial expansion with US$ 608 million in revenue, a 14% annual increase. This growth was driven by a 9% increase in sales volume and a 5% increase in average prices, supported by products such as Zenrelia, Credelio Quattro, and AdTab. The Brazilian market was noted as a key driver for the global evolution of Zenrelia.
The livestock segment reported revenue of US$ 631 million, a 6% reported increase and 4% organic growth.
Entities
AHV International · Elanco Animal Health · European Medicines Agency · Jeff Simmons · Paul Riga